Skip to main content
Normal View

Dáil Éireann debate -
Tuesday, 11 May 1999

Vol. 504 No. 4

Written Answers. - Vaccination Programme.

Denis Naughten

Question:

175 Mr. Naughten asked the Minister for Health and Children if the search of records into the administration of the three-in-one vaccine batch No. 3741 has been completed by all the health boards; the number of children administered with this vaccine batch in each of the health board areas; and if he will make a statement on the matter. [11883/99]

Denis Naughten

Question:

176 Mr. Naughten asked the Minister for Health and Children the follow up procedure to be employed by the health boards following the identification of children who were administered with the three-in-one vaccine batch No. 3741; and if he will make a statement on the matter. [11884/99]

Denis Naughten

Question:

177 Mr. Naughten asked the Minister for Health and Children the number of children who received the three-in-one vaccine batch No. 3741 who have been traced; the number of families who have been contacted following the administration of the vaccine in each of the health board areas; and if he will make a statement on the matter. [11885/99]

Denis Naughten

Question:

178 Mr. Naughten asked the Minister for Health and Children if, further to Parliamentary Question No. 247 of 16 February 1999, the information, if any, he has received from the manufacturers (details supplied) in relation to 14 batches of the three-in-one vaccine; and if he will make a statement on the matter. [11886/99]

Denis Naughten

Question:

179 Mr. Naughten asked the Minister for Health and Children if, further to Parliamentary Question Nos. 245 to 247 of 16 February 1999, the additional information, if any, he has received from the manufacturers of batch No. 3741 of the three-in-one vaccine; and if he will make a statement on the matter. [11887/99]

I propose to take Questions Nos. 175 to 179, inclusive, together.

The health boards have completed the examination of their immunisation records in relation to the extent to which Trivax three-in-one vaccine from certain lots produced from batch no. 3741 was used in the period 1968-70.

The health boards have identified a total of 295 records relating to children who received vaccine from three of the lot numbers concerned. Of these, 183 were in the Mid-Western Health Board area, 109 in the Southern Health Board area and three in the Western Health Board area.

My Department is considering the health boards' responses with a view to determining what, if any, further action is appropriate in this matter.

Glaxo Wellcome Limited, the successor to the company which produced the Trivax vaccine, has indicated to my Department that a variety of tests were used to analyse Trivax in the late 1960s and that all batches of Trivax released for sale complied with the mandatory requirements at that time. The company added that the results of all tests, mandatory and otherwise, together with expert advice which the company had sought, indicate that no other batch gave rise to the same level of potential concern as batch 3741.

Top
Share